Targeting ARPC1B+ Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment

Yang Wu; Jianpeng Zhang; Weixiong Zhu; Xinrui Zhu; Yi Liu; Xin Wang; Tianyu Zhao; Chun Zhang; Zili Zhang; Wenjie Shi; Run Shi; Zhaokai Zhou; Shaohui Xu

doi:10.1111/cpr.70125

Cell Proliferation ›› 2025, Vol. 58 ›› Issue (12) :e70125 DOI: 10.1111/cpr.70125

LETTER TO THE EDITOR

Targeting ARPC1B⁺ Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment

Author information +

¹. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

². Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

³. The Second Clinical Medical College, Lanzhou University, Lanzhou, China

⁴. Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

⁵. Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China

⁶. Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China

⁷. Institute of Social Medicine and Epidemiology, Medical University of Graz, Graz, Austria

⁸. Department of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

⁹. State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, China

¹⁰. Molecular and Experimental Surgery, Clinic for General-, Visceral-, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany

¹¹. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

¹². Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China

¹³. Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, China

wenjie.shi@med.ovgu.de

shirun@njmu.edu.cn

13526278113@163.com

shaohui.xu18@gmail.com

Show less

History +

PDF

Cite this article

Download citation ▾

Yang Wu, Jianpeng Zhang, Weixiong Zhu, Xinrui Zhu, Yi Liu, Xin Wang, Tianyu Zhao, Chun Zhang, Zili Zhang, Wenjie Shi, Run Shi, Zhaokai Zhou, Shaohui Xu. Targeting ARPC1B⁺ Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Cell Proliferation, 2025, 58(12): e70125 DOI:10.1111/cpr.70125

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	T. F. Stoop, A. A. Javed, A. Oba, et al., “Pancreatic Cancer,” Lancet 405, no. 10485 (2025): 1182–1202.

[2]	J. Wang, J. Yang, A. Narang, et al., “Consensus, Debate, and Prospective on Pancreatic Cancer Treatments,” Journal of Hematology & Oncology 17, no. 1 (2024): 92.

[3]	P. E. Saw, Q. Liu, P. P. Wong, and E. Song, “Cancer Stem Cell Mimicry for Immune Evasion and Therapeutic Resistance,” Cell Stem Cell 31, no. 8 (2024): 1101–1112.

[4]	T. Huang, X. Song, D. Xu, et al., “Stem Cell Programs in Cancer Initiation, Progression, and Therapy Resistance,” Theranostics 10, no. 19 (2020): 8721–8743.

[5]	A. Gzil, I. Zarebska, W. Bursiewicz, P. Antosik, D. Grzanka, and L. Szylberg, “Markers of Pancreatic Cancer Stem Cells and Their Clinical and Therapeutic Implications,” Molecular Biology Reports 46, no. 6 (2019): 6629–6645.

[6]	M. Boesch, S. Sopper, A. G. Zeimet, et al., “Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche,” Biochimica et Biophysica Acta 1866, no. 2 (2016): 276–289.

[7]	J. Xie, A. Yang, Q. Liu, et al., “Single-Cell RNA Sequencing Elucidated the Landscape of Breast Cancer Brain Metastases and Identified ILF2 as a Potential Therapeutic Target,” Cell Proliferation 57, no. 11 (2024): e13697.

[8]	G. Wang, S. Wu, Z. Xiong, H. Qu, X. Fang, and Y. Bao, “CROST: A Comprehensive Repository of Spatial Transcriptomics,” Nucleic Acids Research 52, no. D1 (2024): D882–D890.

[9]	M. Posta and B. Gyorffy, “Analysis of a Large Cohort of Pancreatic Cancer Transcriptomic Profiles to Reveal the Strongest Prognostic Factors,” Clinical and Translational Science 16, no. 8 (2023): 1479–1491.

[10]	T. M. Malta, A. Sokolov, A. J. Gentles, et al., “Machine Learning Identifies Stemness Features Associated With Oncogenic Dedifferentiation,” Cell 173, no. 2 (2018): 338–354.

[11]	A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J. P. Mesirov, and P. Tamayo, “The Molecular Signatures Database (MSigDB) Hallmark Gene Set Collection,” Cell Systems 1, no. 6 (2015): 417–425.

[12]	X. Wang, S. Wen, X. Du, et al., “SAA Suppresses Alpha-PD-1 Induced Anti-Tumor Immunity by Driving T(H)2 Polarization in Lung Adenocarcinoma,” Cell Death & Disease 14, no. 11 (2023): 718.

[13]	R. Shi, J. Sun, Z. Zhou, et al., “Integration of Multiple Machine Learning Approaches Develops a Gene Mutation-Based Classifier for Accurate Immunotherapy Outcomes,” NPJ Precision Oncology 9, no. 1 (2025): 54.

[14]	S. F. Boj, C. I. Hwang, L. A. Baker, et al., “Organoid Models of Human and Mouse Ductal Pancreatic Cancer,” Cell 160, no. 1–2 (2015): 324–338.

[15]	M. Ashrafizadeh, K. Luo, W. Zhang, A. Reza Aref, and X. Zhang, “Acquired and Intrinsic Gemcitabine Resistance in Pancreatic Cancer Therapy: Environmental Factors, Molecular Profile and Drug/Nanotherapeutic Approaches,” Environmental Research 240, no. Pt 2 (2024): 117443.

[16]	A. Dirkse, A. Golebiewska, T. Buder, et al., “Stem Cell-Associated Heterogeneity in Glioblastoma Results From Intrinsic Tumor Plasticity Shaped by the Microenvironment,” Nature Communications 10, no. 1 (2019): 1787.

[17]	M. Ke, H. Zhu, Y. Lin, et al., “Actin-Related Protein 2/3 Complex Subunit 1B Promotes Ovarian Cancer Progression by Regulating the AKT/PI3K/mTOR Signaling Pathway,” Journal of Translational Internal Medicine 12, no. 4 (2024): 406–423.

[18]	Z. Gao, J. Xu, Y. Fan, et al., “ARPC1B Promotes Mesenchymal Phenotype Maintenance and Radiotherapy Resistance by Blocking TRIM21-Mediated Degradation of IFI16 and HuR in Glioma Stem Cells,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 323.

[19]	C. Liao, W. Chen, G. Xu, J. Wang, and W. Dong, “High Expression of ARPC1B Correlates With Immune Infiltration and Poor Outcomes in Glioblastoma,” Biochemistry and Biophysics Reports 37 (2024): 101619.

[20]	T. Liu, T. Sun, X. Chen, et al., “Targeting ARPC1B Overcomes Immune Checkpoint Inhibitor Resistance in Glioblastoma by Reversing Protumorigenic Macrophage Polarization,” Cancer Research 85, no. 7 (2025): 1236–1252.